Zyprexa Under Medicare: Shift From Medicaid Means $200 Mil. Less Rebates
Executive Summary
The transfer of "dual eligible" Zyprexa patients from Medicaid to the new Medicare drug benefit means that Lilly's rebate payments to states will be reduced by about $200 mil. per year